฿221.32
-฿1.19(-0.53%)
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿222.51
market.size฿532.76B
volume.trade3.85M
pe.ratio18.80
div.yield2.34%
div.amount฿1.34
diluted.eps8.60
net.income฿26.80B
revenue฿94.19B
earnings.date2026-07-15
eps.estimate2.83
rev.estimate฿24.95B
shares.out2.39B
beta0.263
ex.div.date2026-05-26
div.pay.date2026-06-09
about.stock
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
sectorHealthcare
industryDrug Manufacturers - General
ceoJoaquin Duato
headquartersNew Brunswick,NJ,US
websitehttps://www.jnj.com
employees138.20K
avg.revenue฿681.57K
income.per.emp฿193.95K
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure
